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Abstract
There are about 500,000 new cases of cancer of the esophagus and 400,000 esophageal 
cancer-related deaths recorded annually around the world. The disease is three to four 
times more frequent in men than in women, being the sixth most common cancer and the 
fifth most frequent cancer-related death among men. The prognosis of esophageal cancer 
is quite poor, despite advances in surgical procedures (two-field and three-field lymph 
node dissection) and perioperative management, which is still controversial. The use of 
chemotherapy and radiotherapy in combination with surgery might be a new approach 
for future treatment. Progress in optical technology has led to the development of a new 
minimally invasive surgical approach for the treatment of esophageal cancer, namely 
esophagectomy.
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1. Introduction
There are about 500,000 new cases of cancer of the esophagus and 400,000 esophageal cancer-
related deaths recorded annually around the world. The disease is three to four times more 
frequent in men than in women, being the sixth most common cancer and the fifth most fre-
quent cancer-related death among men [1].
Even though esophageal cancer was not very common in Western populations, the incidence 
of esophageal adenocarcinoma and its related mortality have increased in the USA and 
certain European countries [2]. The incidence of adenocarcinomas involving the esophago-
gastric junction, the distal esophagus and the gastric cardia has recorded a more significant 
increase [3]. The transition from squamous cell carcinoma to Barrett’s metaplasia-associated 
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adenocarcinoma in Western populations could have been determined by the increase in the 
incidence of obesity and obesity-induced reflux [4, 5].
There are two main subtypes of the disease, namely esophageal squamous cell carcinoma 
and esophageal adenocarcinoma. The most common causes of squamous cell carcinoma are 
tobacco and alcohol, and the most common causes of adenocarcinoma are tobacco, obesity 
and acid reflux [5]. There has been a major increase in the incidence of adenocarcinoma in 
North America and Europe, while squamous cell carcinoma is still the most common type of 
esophageal cancer in Asia [6].
The two subtypes of esophageal cancer have different clinical and biological characteristics. 
While squamous cell carcinomas occur in the middle or upper third of the esophagus, adeno-
carcinomas occur in the lower third of the esophagus. Abdominal lymph node metastasis 
is usually present in adenocarcinomas, and the incidence of cervical or upper mediastinal 
lymph node metastasis is more frequent in squamous cell carcinomas. Thus, the therapeutic 
approach is different for each subtype [7].
The prognosis of esophageal cancer is quite poor, despite advances in surgical procedures 
(two-field and three-field lymph node dissection) and perioperative management, which is 
still controversial [7]. The use of chemotherapy and radiotherapy in combination with surgery 
might be a new approach for future treatment. Progress in optical technology has led to the 
development of a new minimally invasive surgical approach for the treatment of esophageal 
cancer, namely esophagectomy. Long-term survival in resectable esophageal cancer is also 
influenced by definitive chemoradiotherapy [8]. Salvage esophagectomy is used in patients 
with esophageal cancer who were treated with chemoradiation as definitive therapy [9].
Although cancer of the esophagus is among the most common cancers in the world, there 
are few studies on this malignancy. There have been significant changes in the epidemiology 
of esophageal cancer in the past 30 years, with a striking increase in incidence in Western 
populations, where the number of adenocarcinomas has exceeded those of the squamous cell 
type [6]. On the other hand, squamous cell carcinoma is the most frequent subtype in Asian 
countries, mainly developing in the middle third of the esophagus, without any dramatic 
increase in the incidence of adenocarcinoma on this continent. New diagnostic, staging, and 
therapeutic options have improved survival rates for esophageal cancer.
Early stage adenocarcinoma of the esophagogastric junction (AEG) could be detected based 
on efficient screening for gastroesophageal reflux disease (GERD) and Barrett’s metaplasia, 
which might be cured using endoscopic ablation or surgery [10].
The infection with Helicobacter pylori harboring the cagA gene seems to be associated with a 
reduced risk of esophageal adenocarcinoma [11, 12].
The potential role of COX-2 inhibitors in the effective chemoprevention of esophageal adeno-
carcinoma, characterized by COX-2 overexpression, is another aspect to be considered [13]. 
The types of surgery for cancer of the esophagus are divided based on the complex lymphatic 
drainage from the esophagus and gastric cardia and their anatomy.
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2. Esophageal resection
Hulscher et al. conducted a meta-analysis and obtained a 20% 5-year survival rate [14] fol-
lowing any of the two approaches. However, there were much higher rates of early morbidity 
and mortality in the case of transthoracic resection. On the other hand, in another study con-
ducted by Hagen et al. [15], better survival rates (41% vs. 14%; p < 0.001) were obtained in 30 
patients following en bloc esophagectomy compared with 39 patients undergoing transhiatal 
esophagectomy, suggesting the use of extended en bloc esophagectomy instead of transhiatal 
resection in the case of carcinoma of the lower third of the esophagus and gastric cardia [15].
Outcomes in esophageal cancer are often poor [16]. The best and most efficient surgical 
method in patients without evidence of spread to other parts of the body is the combination 
between esophagectomy and reconstruction surgery [7]. There are three more frequent min-
imally invasive techniques for esophagectomy: transhiatal esophagectomy, the Ivor Lewis 
esophagectomy (upper midline laparotomy combined with a right posterolateral thoracot-
omy), and the McKeown technique (right thoracotomy, upper midline laparotomy, and left 
neck incision). Several randomized trials compared transhiatal esophagectomy and standard 
transthoracic esophagectomy, showing no significant differences between them. The differ-
ences between transthoracic and transhiatal esophagectomy were examined in three ran-
domized trials [17–21]. The results of these clinical trials showed no significant differences 
between the two approaches in what concerns patient survival. Hulscher et al. [22] conducted 
a randomized trial in patients with adenocarcinoma of the esophagus and gastric cardia (106 
patients with transhiatal esophagectomy and 114 with transthoracic esophagectomy). There 
were lower morbidity rates in the case of transhiatal esophagectomy than in transthoracic 
esophagectomy with extended en bloc lymph node dissection. Despite the absence of statis-
tically significant differences in terms of disease-free, median overall, and quality-adjusted 
survival, there was an improvement in long-term survival of patients with extended trans-
thoracic resection. Asia, especially Japan, accounts for the majority of the more aggressive 
surgery records. Five-year survival rates following three-field lymph node dissection were 
48.7% in a study conducted by Kato et al. [23] and 55.0% in a study by Akiyama et al. [24].
Esophagectomy can be either transhiatal or transthoracic, performed using the Ivor Lewis 
technique (combined laparotomy and right thoracotomy) and the modified McKeown proce-
dure, involving laparotomy, right thoracotomy with neck anastomosis, left thoracotomy, or 
left thoracoabdominal incision [25]. The approach is chosen depending on tumor location and 
surgeon preferences. Good treatment outcomes result from the complexity of these surgical 
procedures, the experience of the surgeons, and intensive care resources [26].
A comprehensive randomized study assessing the differences between the transthoracic and 
the transhiatal approach indicated similar mortality rates for both procedures, whereas mor-
bidity rates were lower for the transhiatal approach. The transthoracic group showed non-sig-
nificant associations between this procedure and overall and disease-free survival. However, 
there was an improvement in locoregional disease-free survival following transthoracic esoph-
agectomy in a subgroup of patients who did not present extensive nodal involvement [27].
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Long-term survival rates following open esophagectomy do not differ significantly when 
comparing these surgical procedures, as shown by various meta-analyses and randomized 
trials [28]. In their study, Tabira et al. [29] recommended the use of three-field lymph node dis-
section in patients with one to four lymph node metastases. As indicated by Shiozaki et al. [30], 
neck dissection might be eliminated in patients with carcinoma in the middle or lower third of 
the esophagus without lymph node metastasis along the recurrent nerve chain. Lerut et al. [31] 
also proved an improvement in patient survival following three-field lymph node dissection.
When comparing three-field with two-field lymph node dissection for squamous cell car-
cinoma of the esophagus, Kato et al. obtained 5-year survival rates of 48.7% for the first 
approach and 33.7% for the second. However, this study was contested due to differences 
in patient characteristics. Isono et al. [32] conducted a nationwide study and obtained better 
survival rates when using three-field dissection instead of the two-field approach. Fujita et al. 
[33] also presented much better survival rates following three-field lymph node dissection 
(p < 0.05) for carcinoma in the upper or middle third of the esophagus spreading to the lymph 
nodes. Still, there were no differences in mortality, morbidity, and postoperative quality of 
life between the two approaches [33]. Radical esophagectomy helps remove ≥80 lymph nodes 
and 5-year survival rates are around 40–60% [34].
3. Minimally invasive surgery
Pulmonary complications after transthoracic esophagectomy are high. The minimally inva-
sive thoracoscopic approach might result in lower morbidity and mortality rates. Being 
minimally invasive, thoracoscopy should replace the open approach. In a study conducted 
by Cuschieri et al. [35], the researchers performed right thoracoscopy (esophagectomy and 
lymph node dissection) in a small group of patients and paved the way for the future use 
of thoracoscopic esophagectomy. This procedure proved to be feasible and even superior 
to open surgery. Nevertheless, the first outcomes using this approach were not significantly 
better than those obtained with the open approach, mainly as a result of the great number of 
pulmonary complications [36–38]. However, a few medical research centers in Japan found 
a new stimulus. For example, Akaishi et al. [39] obtained good outcomes in 39 patients with 
cancer of the esophagus who underwent en bloc esophagectomy with radical lymph node 
dissection via right thoracoscopy, with the following parameters: 200±41 min operating time, 
270±157 ml blood loss, and the number of harvested lymph nodes was 19.7±11. All patients 
survived and there was a modest decrease in vital capacity in 22 of them, without requiring 
postoperative ventilation. A significant finding of the study was that pulmonary complica-
tions were reduced compared with the open procedure.
In their study, Luketich et al. [40] proved that minimally invasive esophagectomy (MIE) is 
efficient and safe in the United States. The study was conducted on 1033 consecutive patients 
and results indicated a significantly lower mortality rate (0.9%), with an 8-day median hos-
pital stay. In a study performed in the United Kingdom, Mamidanna et al. [41] assessed 7502 
patients undergoing esophagectomy (E) and MIE (n = 1.155) and results showed no differences 
in terms of 30-day morbidity and mortality. MIE proved to be safe for use by professionals, 
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without supplementary patient safety risks. Despite the low number of annual esophagec-
tomies (2) per medical center, study results were similar and MIE was preferred in terms 
of perioperative outcomes. On the other hand, there are insufficient and incomplete cancer 
comparative research data. Certain centers noted higher lymph node retrieval following MIE 
with lymph node dissection [42–44], whereas others did not find any considerable differences 
[45]. In a study performed on 168 patients, Palazzo et al. [46] demonstrated that long-term sur-
vival was twice better in patients who underwent MIE (hazard ratio—2.0). Despite significant 
patient and tumor variables, there were concerns related to the ability to reproduce the major 
differences in results obtained for these groups. Additionally, the small number of patients 
might assign any variations to defective regulations.
In a study assessing three-field lymph node dissection, Osugi et al. compared 77 patients with 
squamous cell cancer who underwent minithoracotomy to 72 controls who underwent conven-
tional three-stage treatment. Exceptional outcomes were obtained in terms of lymph node retrieval 
(33 vs. 32), operating time (227 vs. 186 min), reduced vital capacity (15% vs. 22%, p = 0.016), 
3-year survival (70% vs. 60%), and 5-year survival (55% vs. 57%) [44]. Resection via thoracoscopy 
showed almost similar results to open esophagectomy. Moreover, surgical trauma was reduced. 
The differences in outcome between the first 34 and the next 46 patients who underwent surgery 
in the same study group demonstrated the impact of the learning curve on obtaining shorter 
operating times and better results by using this approach. Other advantage is that greater experi-
ence helps reduce postoperative pulmonary complications (5% incidence). Reduced blood loss, 
shorter operating time for thoracoscopy, reduced postoperative respiratory complications and 
higher lymph node retrieval were all observed in the last group [44]. In a study conducted on 222 
patients undergoing thoracoscopic and laparoscopic esophageal resection, Luketich et al. (Ann 
Surg 2003; 238:486–494) showed an incidence rate of pneumonia of 7.7%. A significant finding 
was the reduced length of intensive care unit stay (1 day) and hospital stay (7 days) and the 
1.4% operative mortality. Quality of life indicator was comparable to baseline scores and popula-
tion standards. Nguyen et al. [47] assessed 46 consecutive patients and found similar results to 
Luketich et al. There have also been studies supporting robot-assisted thoracoscopy; however, 
there is still need for further investigation regarding robotic esophagectomy [48].
The results obtained by Biere et al. [49] in the TIME (Traditional Invasive vs. Minimally Invasive 
Esophagectomy) trial comparing the outcomes of 115 British patients who underwent either 
E or MIE showed that besides a decrease in perioperative pulmonary complications, the two 
procedures were more or less similar. However, the main competence of the trial was to show 
differences in short-term outcomes, with lower capacity in pointing out other outcomes. Patient 
outcomes were adapted to a population, improving the ability to perform a multivariate analy-
sis of small differences in survival. There are few data on comparative differences in robot-
assisted esophagectomy. In a study conducted on 43 patients who were treated with MIE (of 
which 11 underwent robot-assisted esophagectomy), Weksler et al. [50] reached the conclusion 
that robot-assisted and conventional procedures were similar. There were not enough patients 
included in the study, the results were disorganized, and there were no cancer data. Our study 
also experiences difficulties due to this aspect when comparing robotic with conventional 
MIE, but we managed to explain certain confounding variables for our outcomes. The limita-
tions of our study are represented by the inability to determine specific MIE approaches (the 
McKeown procedure, the Ivor Lewis approach, and the transhiatal procedure). Earlier studies 
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have  demonstrated that the three procedures have similar outcomes, even though there are dif-
ferences in terms of perioperative complications [51]. Another drawback was the difficulty in 
differentiating between patients who underwent hybrid procedures, such as laparoscopy com-
bined with minithoracotomy, and patients who were treated with total MIE. These limitations 
pave the way for the occurrence of unknown interactions and confounding variables. Currently, 
there are two different clinical trials comparing E to MIE patients, namely the French MIRO trial 
[52] and the British ROMIRO trail [53]. Still, the study that we conducted is the most extensive 
comparative effectiveness research of MIE assessing long-term survival. As a result, MIE deter-
mines poor improvement in perioperative outcomes, with no negative impact on survival rates.
4. Combined modality therapy
4.1. Neoadjuvant chemotherapy
The use of preoperative chemotherapy compared with surgical treatment has been assessed 
in randomized trials in order to obtain improved surgical outcomes. However, the results are 
highly disputed. The three meta-analyses built on these randomized trials showed no differ-
ence in survival when the endpoint was 1-year survival in six of these trials. On the contrary, 
in comparison with surgical treatment, 2-year survival rates were improved following pre-
operative chemotherapy (4.4%) when the endpoint was 2-year survival in seven randomized 
trials [53]. When the meta-analysis was restricted to four recently randomized trials based on 
cisplatin and 5-fluorouracil therapy, there was a 6.3% improvement in 2-year survival. Still, 
this increase did not occur in one meta-analysis where the endpoint was 2-year survival [54]. 
The impact of preoperative chemotherapy is still uncertain.
4.2. Neoadjuvant chemoradiotherapy
Used in Europe and America since the end of the 1980s, preoperative chemoradiotherapy 
determined survival rate improvement in patients with cancer of the esophagus. Despite 
being used on a small scale due to the advanced surgical procedures available in Japan, a 
randomized trial reported the efficiency of hyperthermochemoradiotherapy in esophageal 
cancer [55]. Five meta-analyses built on five to seven randomized trials assess the impact of 
surgery alone, on the one hand, with preoperative chemoradiotherapy used in combination 
with surgery, on the other hand. There were no improvements in survival rates following 
preoperative chemoradiotherapy when the endpoint was 1-year or 2-year survival. When the 
endpoint was 3-year survival, there was an increase in perioperative mortality within 90 days 
after surgery, contrasted by a decrease in local recurrence and an improvement in 3-year sur-
vival rates in analogy to surgery alone (Int J Hyperthermia 1992; 8:289–295). There was a 14% 
decrease in death risk following preoperative chemoradiotherapy when the endpoint was the 
hazard ratio of survival curves [56]. Several reports [57–59] of six randomized trials showed 
higher survival rates following preoperative chemoradiotherapy than after surgery alone. 
Another report focusing on esophageal adenocarcinoma reported much higher survival rates 
following preoperative chemoradiotherapy versus surgery alone [60].
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A meta-analysis of randomized trials conducted in Europe and America reported no improve-
ment in survival with postoperative chemotherapy following curative resection in patients 
with cancer of the esophagus. In contrast, a randomized trial conducted in Japan showed that 
postoperative chemotherapy determined a major improvement in disease-free survival. In 
conclusion, postoperative chemotherapy recommends itself as an efficient measure to prevent 
recurrence after surgery.
4.3. Adjuvant radiotherapy
Four randomized trials assessing the differences between surgery alone and postoperative 
radiotherapy (45–65 Gy) reported no major improvements in survival. However, there was a 
decrease in local recurrence in the irradiated area following postoperative radiotherapy. No 
major improvements in survival were observed in a meta-analysis of these randomized trials. 
In conclusion, postoperative radiotherapy is not a conventional treatment option.
4.4. Postoperative outcome
The incidence of postoperative mortality was assessed in a considerable number of studies 
[61–65], fewer assessed in-hospital mortality, and 30-day mortality was determined in two 
studies [66]. Values were higher in patients who were treated with salvage esophagectomy 
after definitive chemoradiotherapy (23 patients—9.50%) than in patients who treated with 
planned esophagectomy after neoadjuvant chemoradiotherapy (29 patients—4.07%). Pooling 
of results validated the much higher incidence of postoperative mortality in the case of sal-
vage esophagectomy (prevalence odds ratios (POR) = 3.02; 95% CI 1.64–5.58; p < 0.001).
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